Jack A. Khattar - 11 May 2023 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Role: President, CEO, Director
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Issuer symbol: SUPN
Transactions as of: 11 May 2023
Transactions value $: -$547,232
Form type: 4
Filing time: 12 May 2023, 17:00:35 UTC
Previous filing: 08 May 2023
Next filing: 08 Jun 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SUPN	Common Stock	Options Exercise	$0	+31,250	+3.75%	$0	864,272	11 May 2023	Direct	F1
transaction	SUPN	Common Stock	Tax liability	-$547,232	-15,005	-1.74%	$36.47	849,267	11 May 2023	Direct	F2
holding	SUPN	Common Stock						1,038,950	11 May 2023	By the KBT Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SUPN	Performance Share Unit	Options Exercise	$0	-31,250	-100%	$0^*	0	11 May 2023	Common Stock	31,250	$0	Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares of common stock received upon the settlement of certain performance share units granted to the Reporting person on May 3, 2022.
F2	Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the PSU vesting.
F3	On May 3, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period.